COVID-19 pandemic demands a swift response to find therapeutic tools that effectively
reduce morbidity and mortality. Despite initial fears, evidence from retrospective …

Abstract Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects
beyond their antihypertensive properties, including reduction of inflammation. ARBs directly …

Background SARS-CoV-2 binds to membrane-bound angiotensin-converting enzyme 2
(ACE2) which may result in downregulation of membrane-bound ACE2. ACE2 is a key …

Objective To determine whether disrupting the renin angiotensin system with angiotensin
receptor blockers will improve clinical outcomes in people with covid-19. Design CLARITY …

Introduction The novel coronavirus disease 2019 (COVID-19), caused by the severe acute
respiratory system-coronavirus-2 (SARS-CoV-2), is an important medical problem …

The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II
receptor blockers (ARBs) on COVID-19 disease severity have generated considerable …

Background The association of ACE inhibitors (ACEIs) and angiotensin II receptor blockers
(ARBs) with disease severity of patients with COVID-19 is still unclear. We conducted a …

Some Authors recently suggested that angiotensin-converting enzyme (ACE) inhibitors and
angiotensin II receptor blockers (ARBs) should be discontinued, even temporarily, given the …

Since December 2019, the coronavirus 2019 (COVID-19) pandemic has rapidly spread and
overwhelmed healthcare systems worldwide, urging physicians to understand how to …

SARS-CoV-2 infection and its clinical manifestations (COVID-19) quickly evolved to a
pandemic and a global public health emergency. The limited effectivity of available …